Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial…
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics with an undisclosed purchase priceNEW YORK…
Kennewick, WA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to provide shareholders with a positive…
New patent covers IBSRELA® and XPHOZAH® and expires in 2042WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq:…
Fort Pierce, FL, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Caring Brands Inc. (Nasdaq: CABR) today announced the issuance of two…
This clearance enables the next phase of development aimed ultimately at removing the adjunct use in the US The newly…
Company highlights accelerating access and revenue growth for ARBLI™ and confirms REZENOPY™ launch timeline, addressing a combined US annual losartan…
This is the first trial combining Allarity’s stenoparib with another anti-cancer agent Stenoparib’s favorable safety profile supports potential for…
A major regulatory milestone positioning Byonyks as a new entrant in home-based renal careCHICAGO, Feb. 03, 2026 (GLOBE NEWSWIRE) --…
Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotype BLA resubmitted to U.S.…